Trial Profile

Empagliflozin and the Preservation of Beta-cell Function in Women With Recent Gestational Diabetes

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Empagliflozin (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms EMPA post-GDM

Most Recent Events

01 Dec 2025 Primary endpoint has not been met. (Baseline-adjusted ISSI-2 at 48-weeks)
01 Dec 2025 Results published in the Diabetes, Obesity and Metabolism
07 Mar 2025 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com